|
|
Forteo: A Case Study in Launching a Breakthrough Therapy in a Saturated MarketPublished by: Decision Resources Published: Oct. 30, 2006 - 16 Pages Price reduced due to age.Table of Contents
AbstractThe osteoporosis market has grown nearly 20% per year since 2000, presenting many opportunities for drug manufacturers. However, several effective, well-established, and reasonably priced agents dominate the market. Even novel therapies satisfying a distinct need face tremendous challenges when launched in this competitive arena.Get the Answers You Need to Shape Your Strategy Eli Lilly's bone-building drug Forteo (teriparatide) was a promising breakthrough treatment for osteoporosis that achieved disappointing sales and relatively low acceptance among patients and physicians. Why did Forteo fail to meet early expectations for its use? Several issues during Forteo's development phase greatly affected its launch and initial uptake. What are some problems that can hinder the uptake of a breakthrough therapy? What lessons can be learned from Forteo's development and launch? Even an effective novel agent may face challenges when placed in a market that is saturated with well-established therapies. What factors must drug developers consider when developing and launching new agents? Scope Overview of osteoporosis: disease description, prevalence, and economic burden. Current market for osteoporosis therapies: overview of common agents used to treat osteoporosis. Case study of Forteo: development and approval, launch and early performance, outlook, lessons to be learned. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||